Minova Life Science

Minova life sciences - Pharmaceutical company

Fexocon-AM Tablets

COMPOSITION – Each film coated tablet contains: Montelukast Sodium IPEquivalent to Montelukast 10mg + Fexofenadine Hydrochloride IP 120mg + Acebrophylline 200mg(As Sustained Release form)


Montelukast Sodium

•Montelukast sodium is an oral, potent, and selective antagonist at CysLT Rs. which mediates the bronchoconstrictor and proinflammatory actions of the CysLTs in asthma and Asthma Rhinitis.

 – Both as monotherapy or in combination with inhaled corticosteroids, montelukast produced clinically relevant improvements in asthma-related parameters, including symptoms, lung function parameters, quality of life, and the number of asthma exacerbations.

Fexofenadine Hydrochloride

– Fexofenadine hydrochloride (HCI) is a second-generation, selective histamine Hi-receptor antagonist, approved to relieve SAR symptoms in adults and children.

Fexofenadine, the active metabolite of terfenadine, is a selective histamine Hi receptor antagonist that displays some anti-inflammatory properties. 


•Acebrophylline is an airway mucus regulator with anti-inflammatory action that reduces the hyper-responsive, inflammatory condition more markedly and more promptly than ambroxol.

•Therapeutically effective in reducing the frequency of episodes of bronchial obstruction and reducing the need for $2-agonists, and improving indexes of ventilatory function.

Explore other products

Scroll to Top